209 related articles for article (PubMed ID: 35790143)
21. Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab.
Schlegel P; Lang P; Zugmaier G; Ebinger M; Kreyenberg H; Witte KE; Feucht J; Pfeiffer M; Teltschik HM; Kyzirakos C; Feuchtinger T; Handgretinger R
Haematologica; 2014 Jul; 99(7):1212-9. PubMed ID: 24727818
[TBL] [Abstract][Full Text] [Related]
22. Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study.
Goebeler ME; Knop S; Viardot A; Kufer P; Topp MS; Einsele H; Noppeney R; Hess G; Kallert S; Mackensen A; Rupertus K; Kanz L; Libicher M; Nagorsen D; Zugmaier G; Klinger M; Wolf A; Dorsch B; Quednau BD; Schmidt M; Scheele J; Baeuerle PA; Leo E; Bargou RC
J Clin Oncol; 2016 Apr; 34(10):1104-11. PubMed ID: 26884582
[TBL] [Abstract][Full Text] [Related]
23. Clinical utilization of blinatumomab and inotuzumab immunotherapy in children with relapsed or refractory B-acute lymphoblastic leukemia.
Contreras CF; Higham CS; Behnert A; Kim K; Stieglitz E; Tasian SK
Pediatr Blood Cancer; 2021 Jan; 68(1):e28718. PubMed ID: 33098744
[TBL] [Abstract][Full Text] [Related]
24. A Systematic Review of Blinatumomab in the Treatment of Acute Lymphoblastic Leukemia: Engaging an Old Problem With New Solutions.
Halford Z; Coalter C; Gresham V; Brown T
Ann Pharmacother; 2021 Oct; 55(10):1236-1253. PubMed ID: 33435716
[TBL] [Abstract][Full Text] [Related]
25. Real-world use of blinatumomab in adult patients with B-cell acute lymphoblastic leukemia in clinical practice: results from the NEUF study.
Boissel N; Chiaretti S; Papayannidis C; Ribera JM; Bassan R; Sokolov AN; Alam N; Brescianini A; Pezzani I; Kreuzbauer G; Zugmaier G; Foà R; Rambaldi A
Blood Cancer J; 2023 Jan; 13(1):2. PubMed ID: 36599847
[TBL] [Abstract][Full Text] [Related]
26. Real-world evidence on treatment pattern, effectiveness, and safety of blinatumomab in Chinese patients with B-cell acute lymphoblastic leukemia.
Zhou H; Wu X; Yang Z; Lu S; Zhang X; Yang X; Chen S; Wu D; Miao M
Invest New Drugs; 2024 Jun; 42(3):299-308. PubMed ID: 38662275
[TBL] [Abstract][Full Text] [Related]
27. Blinatumomab for Acute Lymphoblastic Leukemia: The First Bispecific T-Cell Engager Antibody to Be Approved by the EMA for Minimal Residual Disease.
Ali S; Moreau A; Melchiorri D; Camarero J; Josephson F; Olimpier O; Bergh J; Karres D; Tzogani K; Gisselbrecht C; Pignatti F
Oncologist; 2020 Apr; 25(4):e709-e715. PubMed ID: 32297447
[TBL] [Abstract][Full Text] [Related]
28. Molecular response with blinatumomab in relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
Gökbuget N; Kantarjian HM; Brüggemann M; Stein AS; Bargou RC; Dombret H; Fielding AK; Heffner L; Rigal-Huguet F; Litzow M; O'Brien S; Zugmaier G; Gao S; Nagorsen D; Forman SJ; Topp MS
Blood Adv; 2019 Oct; 3(20):3033-3037. PubMed ID: 31648325
[TBL] [Abstract][Full Text] [Related]
29. Blinatumomab in pediatric relapsed/refractory B-cell acute lymphoblastic leukemia: RIALTO expanded access study final analysis.
Locatelli F; Zugmaier G; Mergen N; Bader P; Jeha S; Schlegel PG; Bourquin JP; Handgretinger R; Brethon B; Rössig C; Kormany WN; Viswagnachar P; Chen-Santel C
Blood Adv; 2022 Feb; 6(3):1004-1014. PubMed ID: 34979020
[TBL] [Abstract][Full Text] [Related]
30. High tumor burden before blinatumomab has a negative impact on the outcome of adult patients with B-cell precursor acute lymphoblastic leukemia. A real-world study by the GRAALL.
Cabannes-Hamy A; Brissot E; Leguay T; Huguet F; Chevallier P; Hunault M; Escoffre-Barbe M; Cluzeau T; Balsat M; Nguyen S; Pasquier F; Alexis M; Lheritier V; Pastoret C; Delabesse E; Clappier E; Dombret H; Boissel N
Haematologica; 2022 Sep; 107(9):2072-2080. PubMed ID: 35263986
[TBL] [Abstract][Full Text] [Related]
31. Clinical applications and safety evaluation of the new CD19 specific T-cell engager antibody construct blinatumomab.
Wilke AC; Gökbuget N
Expert Opin Drug Saf; 2017 Oct; 16(10):1191-1202. PubMed ID: 28825327
[TBL] [Abstract][Full Text] [Related]
32. Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies.
Viardot A; Locatelli F; Stieglmaier J; Zaman F; Jabbour E
Ann Hematol; 2020 Oct; 99(10):2215-2229. PubMed ID: 32856140
[TBL] [Abstract][Full Text] [Related]
33. Blinatumomab for the Treatment of Philadelphia Chromosome-Negative, Precursor B-cell Acute Lymphoblastic Leukemia.
Wolach O; Stone RM
Clin Cancer Res; 2015 Oct; 21(19):4262-9. PubMed ID: 26283683
[TBL] [Abstract][Full Text] [Related]
34. Low leukemia burden improves blinatumomab efficacy in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
Queudeville M; Stein AS; Locatelli F; Ebinger M; Handgretinger R; Gökbuget N; Gore L; Zeng Y; Gokani P; Zugmaier G; Kantarjian HM
Cancer; 2023 May; 129(9):1384-1393. PubMed ID: 36829303
[TBL] [Abstract][Full Text] [Related]
35. Benefit-Risk Assessment of Blinatumomab in the Treatment of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia.
Stein A; Franklin JL; Chia VM; Arrindell D; Kormany W; Wright J; Parson M; Amouzadeh HR; Choudhry J; Joseph G
Drug Saf; 2019 May; 42(5):587-601. PubMed ID: 30565020
[TBL] [Abstract][Full Text] [Related]
36. Safety and efficacy of blinatumomab: a real world data.
Apel A; Ofran Y; Wolach O; Shimony S; Ram R; Levi I; Zektser M; Koren-Michowitz M
Ann Hematol; 2020 Apr; 99(4):835-838. PubMed ID: 32076826
[TBL] [Abstract][Full Text] [Related]
37. Dose-Dense Mini-Hyper-CVD, Inotuzumab Ozogamicin and Blinatumomab Achieves Rapid MRD-Negativity in Philadelphia Chromosome-Negative B-cell Acute Lymphoblastic Leukemia.
Short NJ; Jabbour E; Jamison T; Paul S; Cuglievan B; McCall D; Gibson A; Jain N; Haddad FG; Nasr LF; Marx KR; Rausch C; Savoy JM; Garris R; Ravandi F; Kantarjian H
Clin Lymphoma Myeloma Leuk; 2024 Apr; 24(4):e168-e173. PubMed ID: 38212207
[TBL] [Abstract][Full Text] [Related]
38. CD19 expression in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia pre- and post-treatment with blinatumomab.
Mejstrikova E; Klinger M; Markovic A; Zugmaier G; Locatelli F
Pediatr Blood Cancer; 2021 Dec; 68(12):e29323. PubMed ID: 34519430
[TBL] [Abstract][Full Text] [Related]
39. VANDA regimen followed by blinatumomab leads to favourable outcome in patients with Philadelphia chromosome-negative B-precursor acute lymphoblastic leukaemia in first relapse.
Heraudet L; Galtier J; Favre S; Peyraud F; Cazaubiel T; Leroy H; Mottal N; Gros FX; Forcade E; Clément L; Dumas PY; Pigneux A; Leguay T
Br J Haematol; 2022 Aug; 198(3):523-527. PubMed ID: 35524489
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of bispecific T-cell engager (BiTE) antibody blinatumomab for the treatment of relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin's lymphoma: a systemic review and meta-analysis.
Yu J; Wang W; Huang H
Hematology; 2019 Dec; 24(1):199-207. PubMed ID: 30479190
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
